UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,335,743 B2
APPLICATION NO. : 10/684957
DATED : February 26, 2008
INVENTOR(S) : Andrew A. Welcher et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page

In column 1, item (73), Assignee insert --**Medarex, Inc.**, Princeton, NJ (US)--.

In column 2, line 11, under "OTHER PUBLICATIONS", after "et al." delete "urrent" and substitute --Current-- in its place.

Page 2, column 1, line 30, under "OTHER PUBLICATIONS", after "directed" delete "twards" and substitute --towards-- in its place.

Page 2, column 1, line 36, under "OTHER PUBLICATIONS", after "1990;" delete "37" and substitute --27-- in its place.

Page 2, column 1, line 59, under "OTHER PUBLICATIONS", after "Collagen-" delete "Indiced" and substitute --Induced-- in its place.

Page 2, column 2, line 2, after "therapy of" delete "Rherapy" and substitute --Therapy-- in its place.

Page 2, column 2, line 7, after "[Suppl 11]:" delete "69-43" and substitute --39-43-- in its place.

Page 2, column 2, line 24, after "Autoimmune" delete "Disbetes" and substitute --Diabetes-- in its place.

Page 2, column 2, line 25, before "-Prone" delete "Disbetes" and substitute --Diabetes-- in its place.

Page 2, column 2, line 69, before "of a monoclonal" delete "effexts" and substitute --effects-- in its place.

Page 3, column 1, line 6, before "Clinical Trial" delete "Prelimnary" and substitute --Preliminary-- in its place.

Page 3, column 1, line 24, delete "Difersity" and substitute --Diversity-- in its place.

In column 5, line 22, after "SEQ" delete "I)" and substitute --ID-- in its place.

In column 11, line 15, after "acids," delete "wherein" (second occurrence).

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,335,743 B2
APPLICATION NO. : 10/684957
DATED : February 26, 2008
INVENTOR(S) : Andrew A. Welcher et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification

In column 22, line 59, after "or equal to" delete "than".

In column 23, line 40, delete "IFN-γ antibody" and substitute --IFN-γ:antibody-- in its place.

In column 26, line 35, after "corresponding to" delete "CDR's" and substitute --CDRs-- in its place.

In column 31, line 47, after "no light chains." delete "Muldermans" and substitute --Muyldermans-- in its place.

In column 40, line 55, immediately after "active molecule" insert --.-- (period).

In column 45, line 49, before "was concentrated" delete "(hu-IFN-γ" and substitute --(hu-IFN-γ)-- in its place.

In column 46, line 57, immediately after "incubated at 4° C" delete "." (period).

In column 47, line 61, immediately after "at 4° C" delete "." (period).

In column 54, about line 61, before "for 20-24 hours," delete "." (period).

Signed and Sealed this

Eighteenth Day of November, 2008



JON W. DUDAS
Director of the United States Patent and Trademark Office